

Press release

January 10th, 2016

Biofina Diagnostics S.L has been awarded with a Seal of Excellence by the European Commission following the presentation of its project proposal UROBEST 'UROthelial carcinoma Biomarker based diagnostic tEST' Submitted under the Horizon 2020's SME instrument phase 2 call H2020-SMEInst-2014-2015 (H2020-SMEINST-2-2015) of 25 November 2015 in the area of Clinical research for the validation of biomarkers and/or diagnostic medical devices.

After being evaluated by an international panel of independent experts UROBEST was successful in a highly competitive evaluation process as an innovative project proposal. This means passing all stringent Horizon 2020 assessment thresholds for the 3 award criteria: EXCELLENCE, IMPACT, QUALITY AND EFFICIENCY OF IMPLEMENTATION required to receive funding from the EU budget Horizon 2020.

The European Commission recommends this proposal for funding by other sources since Horizon 2020 resources available for this specific Call were already allocated following a competitive ranking.

Metas Biotech consultants have contributed to the preparation of this application to the SME Instrument phase 2 Grant and have since been advising Biofina Diagnostics in the definition of their business plan.

Biofina Diagnostics S.L. (www.biofinadx.com) is a new corporate vehicle incorporated to further develop and take UROBEST to the market, a bladder cancer diagnostic test based on RT-qPCR technology. The company holds the exclusive exploitation and commercialization rights on Fina Biotech's patents (www.finabiotech.es) protecting the diagnostic method. UROBEST has already been validated in clinical studies in more than 500 patients and has proven to have better sensitivity and specificity than competitive products (10-gene signature results: SN=80% and SP=94%). Biofina Diagnostics is currently exploring partnering opportunities that support the introduction of the test into the market both in Europe and the United States. UROBEST® is a registered trademark in the Spanish Patent and Trademark Office (OEPM).

Metas Biotech, S.L. (www.metasbio.com) is a consulting firm specialized in providing business development support and financial advisory services to companies in the life sciences industry.



Biofina Diagnostics S.L.

Headquarters and offices: Calle Camino de las Huertas, 2, Edif. 1
28223 Pozuelo de Alarcón (Madrid) SPAIN – Tel: +34 91 799 15 64

info@biofinadx.com - www.biofinadx.com



★ SEAL OF ★
EXCELLENCE

*Certificate delivered by the European Commission,
as the institution managing Horizon 2020,
the EU Framework Programme for Research and Innovation 2014-2020*

The project proposal **718366, UROBEST**

UROthelial carcinoma Biomarker based diagnostic tEST

Submitted under the Horizon 2020's **SME instrument phase 2**
call **H2020-SMEInst-2014-2015 (H2020-SMEINST-2-2015)** of **25 November 2015**
in the area of

Clinical research for the validation of biomarkers and/or diagnostic medical devices

by

BIOFINA DIAGNOSTICS SL

CAMINO DE LAS HUERTAS 2 EDIFICIO 1
28223 POZUELO DE ALARCON
Spain

following evaluation by an international panel of independent experts

**WAS SUCCESSFUL IN A HIGHLY COMPETITIVE EVALUATION PROCESS*
AS AN INNOVATIVE PROJECT PROPOSAL**

This proposal is recommended for funding by other sources since Horizon 2020 resources available for this specific Call were already allocated following a competitive ranking.

* This means passing all stringent Horizon 2020 assessment thresholds for the 3 award criteria (excellence, impact, quality and efficiency of implementation) required to receive funding from the EU budget Horizon 2020.

Corina Crețu,
Commissioner for
Regional Policy

Carlos Moedas,
Commissioner for Research,
Science and Innovation

Brussels, 08/02/2016

Nota de prensa

10 de Enero de 2016

Biofina Diagnostics S.L ha recibido el Sello de Excelencia de la Comisión Europea tras la presentación de su proyecto UROBEST “*UROthelial carcinoma Biomarker based diagnostic tEST*”, un test no invasivo para el diagnóstico de cáncer de vejiga. La propuesta fue presentada el 25 de noviembre de 2015 en el marco del Instrumento PYME Fase 2 perteneciente al programa Horizonte 2020 dentro de la convocatoria H2020-SMEInst-2014-2015 (H2020-SMEINST-2-2015) en el área Investigación clínica para la validación de biomarcadores y/o dispositivos médicos para el diagnóstico.

Después de ser valorado por un panel internacional de expertos independientes en un proceso de evaluación altamente competitivo, UROBEST ha sido considerado como un proyecto innovador; ha superado con éxito los exigentes umbrales establecidos por el programa H2020 para los tres criterios de concesión: EXCELENCIA, IMPACTO, CALIDAD Y EFICIENCIA EN LA IMPLEMENTACIÓN requeridos para recibir la financiación del presupuesto de la Unión Europea.

La Comisión Europea recomienda la financiación de UROBEST por otras fuentes al haber sido los recursos disponibles para esta convocatoria del programa H2020 ya adjudicados según un proceso competitivo.

Consultores de Metas Biotech han contribuido a la preparación de esta solicitud y dan soporte a Biofina Diagnostics en la definición de su plan de negocio

Biofina Diagnostics S.L. (www.biofinadx.com) es una compañía que nace para desarrollar y llevar al mercado UROBEST®, un test para el diagnóstico no invasivo de cáncer de vejiga mediante tecnología RT-qPCR. La compañía ostenta en exclusiva los derechos para la explotación y comercialización sobre las patentes que protegen el método diagnóstico, pertenecientes a Fina Biotech (www.finabiotech.es). UROBEST ha sido validado en estudios clínicos en más de 500 pacientes y ha demostrado mejor sensibilidad y especificidad que productos competidores (SN=80% y SP=94% para la firma de 10 genes). Biofina Diagnostics está explorando actualmente oportunidades de colaboración para la introducción del test en Europa y Estados Unidos. UROBEST® es una marca registrada en la Oficina Española de Patentes y Marcas (OEPM).

Metas Biotech, S.L. (www.metasbio.com) es una firma especializada en el asesoramiento estratégico y búsqueda de financiación para empresas del ámbito de ciencias de la vida.



Biofina Diagnostics S.L.

Headquarters and offices: Calle Camino de las Huertas, 2, Edif. 1
28223 Pozuelo de Alarcón (Madrid) SPAIN – Tel: +34 91 799 15 64

info@biofinadx.com - www.biofinadx.com